Sun Pharmaceutical Industries declines on getting warning letter from USFDA for Dadra facility
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Sun Pharmaceutical Industries is currently trading at Rs. 1481.00, down by 23.15 points or 1.54% from its previous closing of Rs. 1504.15 on the BSE.
The scrip opened at Rs. 1489.95 and has touched a high and low of Rs. 1489.95 and Rs. 1475.55 respectively. So far 26550 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1638.70 on 05-Apr-2024 and a 52 week low of Rs. 977.50 on 23-Jun-2023.
Last one week high and low of the scrip stood at Rs. 1530.00 and Rs. 1475.55 respectively. The current market cap of the company is Rs. 355317.52 crore.
The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 36.54% and 8.97% respectively.
Sun Pharmaceutical Industries has received warning letter from US Food and Drug Administration (USFDA) for its Dadra facility. The Warning Letter summarizes violations with respect to Current Good Manufacturing Practice (cGMP) regulations. The contents of the Warning Letter shall be made public by the USFDA in due course.
In April 2024, USFDA has issued Official Action Indicated (OAI) status to Dadra facility. USFDA had conducted an inspection at Company’s Dadra facility from December 4, 2023 to December 15, 2023.
Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
